https://www.selleckchem.com/pr....oducts/nec-1s-7-cl-o
Background Health technology assessment (HTA) has increased in importance in supporting payer decision making by assessing the relative effectiveness and cost effectiveness of new medicines. Thus, pharmaceutical companies need to address the HTA requirements early during development to improve reimbursement outcomes. Currently, there is a lack of research to assess the impact of HTA on development and jurisdictional outcome from companies' perspectives. This study aimed to assess companies' HTA strategy and characterise HTA p
Мне нравится
Комментарий
Перепост
